$OPK's US National 4Kscore launch will be huge!

[b]$OPK's US National 4Kscore launch will be huge![/b]

OURLab provides OPKO with a commercial platform to support the near-term U.S. commercial launch of its novel panel of kallikrein biomarkers and associated algorithm (4Kscore™) for the detection of prostate cancer. The OPKO 4Kscore™ is the result of a decade of research by scientists in Europe and the U.S. and has been [b]demonstrated in more than 10,000 patients to predict the probability of positive biopsies in men suspected of having prostate cancer[/b]. Extensive studies have shown that the use of the 4Kscore™ may [b]reduce the number of unnecessary prostate biopsies by 50%[/b] or more, avoiding the frequent complications of pain, bleeding, and infection, which sometimes require hospitalization. The data indicate that even with the significant reduction in the number of biopsies performed, the probability of delaying diagnosis of a high grade cancer was only 0.6%. Men whose 4Kscore™ is low enough to not lead to biopsies would be followed with active surveillance by the urologist.

http://finance.yahoo.com/news/opko-health-acq...00951.html

[i]This procedure is revolutionary. It will be a huge convenience and will dramatically increase the safety of prostate diagnostics in the near future![/i]